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Dose-Ranging Trial of Enoxaparin for Unstable Angina: Results of
TIMI 11A
THE THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI) 11A
TRIAL INVESTIGATORS*
Boston, Massachusetts
Objectives. The Thrombolysis in Myocardial Infarction (TIMI)
11A trial compared the safety and tolerability of two weight-
adjusted regimens of subcutaneous injections of enoxaparin, a low
molecular weight heparin, in patients with unstable angina/
non–Q wave myocardial infarction (NQMI).
Background. The optimal dose of enoxaparin in patients with
arterial disorders has not been established.
Methods. Patients with unstable angina/NQMI were treated
over a 14-day period in an open label dose-ranging trial. During
the in-hospital phase, patients received either 1.25 mg/kg body
weight (dose tier 1) or 1.0 mg/kg (dose tier 2) of enoxaparin
subcutaneously every 12 h. A fixed dose of either 60 mg (body
weight >265 kg) or 40 mg (body weight <65 kg) was administered
subcutaneously every 12 h after hospital discharge.
Results. In an initial cohort of 321 patients (dose tier 1), the
rate of major bleeding through 14 days was 6.5% and occurred
predominantly at instrumented sites. In a second cohort of 309
patients (dose tier 2), the rate of major hemorrhage was reduced
to 1.9%. In both dose tiers, only 3% to 5% of patients withdrew
consent for subcutaneous injections during the home treatment
phase. Through 14 days, the incidence of death, recurrent myo-
cardial infarction or recurrent ischemia requiring revasculariza-
tion was 5.6% in dose tier 1 and 5.2% in dose tier 2.
Conclusions. An acute phase regimen of enoxaparin (1.0 mg/kg
every 12 h) is associated with an acceptable rate of major
hemorrhage during the in-hospital phase. There is a high rate of
patient compliance during the home treatment phase. A Phase III
trial is now underway to test the benefits of uninterrupted
treatment with enoxaparin during both the in-hospital and out-
patient treatment phases.
(J Am Coll Cardiol 1997;29:1474–82)
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Experimental and clinical observations (1–7) suggest that both
platelet activation and thrombin generation are important in
the pathophysiology of unstable angina and non–Q wave
myocardial infarction (NQMI), leading to the recommenda-
tion that aspirin and intravenous heparin be prescribed to treat
these conditions. When unfractionated heparin is adminis-
tered, there is wide variability in the anticoagulant effect
caused by heparin binding to several plasma proteins (8,9). The
amount of these plasma proteins varies among disease states
and among normal subjects. Response to unfractionated hep-
arin is therefore unpredictable, and anticoagulation blood
monitoring is mandatory.
In contrast, low molecular weight heparins (LMWHs) have
minimal protein binding, excellent bioavailability and a pre-
dictable anticoagulant response (8,10,11). LMWHs also have a
number of potential safety advantages compared with unfrac-
tionated heparin. Capillary permeability to plasma proteins
and microvascular bleeding is increased by unfractionated
heparin (by formation of a protein–glycosaminoglycan com-
plex) but not by LMWH (12). LMWHs are also associated with
a reduced potential for thrombocytopenia (13).
Enoxaparin, a LMWH (4,300 daltons) with an anti-Factor
Xa (anti-Xa)/anti-Factor IIa (anti-IIa) ratio of 3:1, is approved
in several countries for the prevention and treatment of deep
vein thrombosis (14). On the basis of clinical trial results and
studies in normal volunteers, a range of mean anti-Xa activity
of 0.5 to 1.0 IU/ml was found to be effective for treatment of
venous disorders (15); however, the optimal dose for treatment
of arterial disorders is unknown. The purpose of the present
Phase II trial (Thrombolysis in Myocardial Infarction [TIMI]
11A) was to evaluate the safety and tolerability of two doses of
enoxaparin in patients with unstable angina/NQMI, in prepa-
ration for a future trial comparing enoxaparin and unfraction-
ated heparin.
Methods
The trial was conducted between July 1995 and January
1996 at 45 enrolling centers in the United States, as described
in the Appendix.
Eligibility criteria. To be eligible for inclusion in the trial,
patients must have had evidence of ischemic heart disease and
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experienced unstable angina/NQMI, with one of the following
three presentations within the preceding week: 1) rest angina
$5 min; 2) new-onset angina (Canadian Cardiovascular Soci-
ety classification III or greater severity, beginning within 2
months of presentation); or 3) increasing angina (previously
diagnosed angina that was distinctly more frequent, longer in
duration or occurring at a lower threshold). To confirm the
presence of ischemic heart disease, patients must have met at
least one of the following criteria: 1) history of typical myocar-
dial ischemic-type discomfort; 2) electrocardiographic changes
(ST segment deviation or T wave inversion, or both) in
association with ischemic discomfort; 3) a history of previous
myocardial infarction; 4) positive results on a previous exercise
tolerance test; 5) previous coronary artery bypass graft surgery
(CABG) or percutaneous transluminal coronary angioplasty
(PTCA); or 6) a previous coronary angiogram showing a 50%
stenosis of a major epicardial coronary vessel.
Patients were excluded from the study if any of the follow-
ing were present: 1) evolving Q wave myocardial infarction or
thrombolytic therapy within 24 h of enrollment or intention to
administer thrombolytic therapy for the patient’s presenting
chest pain syndrome; 2) creatinine $2.0 mg/dl; 3) CABG
within the previous 2 months; 4) history of heparin-induced
thrombocytopenia; 5) contraindications to anticoagulation or
aspirin, including intracerebral hemorrhage ,2 months; 6) an
international normalized ratio .1.4 or a continuous infusion of
unfractionated heparin; or 7) other existing medical condition,
such as the presence of a prosthetic heart valve, requiring
continuous anticoagulation.
Study protocol. TIMI 11A was an open label study de-
signed to evaluate the safety and tolerability of two doses of
enoxaparin in treatment regimens consisting of two phases: 1)
an in-hospital phase (intravenous bolus of 30 mg followed
immediately by subcutaneous injection every 12 h of a weight-
adjusted dose) for a minimum of 48 h; and 2) an outpatient
phase of prolonged fixed subcutaneous dosing (60 mg for
patients $65 kg and 40 mg for patients ,65 kg) every 12 h. In
patients undergoing diagnostic or successful interventional
catheterization procedures, the fixed dose regimen of enoxapa-
rin was started before hospital discharge and was continued as
outpatient therapy. The total treatment period, including the
weight-adjusted and fixed-dose periods, was 14 days.
The original plan was for an ascending dose-ranging trial to
evaluate a weight-adjusted dose of enoxaparin of 1.25 mg/kg
body weight every 12 h (dose tier 1) in the first cohort of
patients and 1.5 mg/kg every 12 h in a second group of patients.
However, because of an unacceptable rate of major hemor-
rhage observed after enrolling 321 patients in the 1.25-mg/kg
every 12 h dose (see Statistical methods), the trial was recon-
figured as a descending dose-ranging trial, with the second
cohort (309 patients) receiving 1.0 mg/kg every 12 h (dose tier
2).
During the course of the treatment period, patients could
undergo diagnostic catheterization either with the study drug,
with no anticoagulation or with unfractionated heparin at the
discretion of the treating physician. All interventional coronary
procedures were to be performed using unfractionated heparin
after a minimum activated clotting time of 350 s had been
achieved, followed subsequently by readministration of study
drug.
After diagnostic and interventional catheterization proce-
dures, the arterial sheath was to be removed no sooner than 7
to 8 h after the previous enoxaparin dose (i.e., beyond the peak
anti-Xa effect). For patients undergoing a diagnostic catheter-
ization or a successful interventional procedure, subcutaneous
injections of enoxaparin every 12 h were restarted in the fixed
dose described earlier at least 24 h after the last subcutaneous
injection. For those patients undergoing complicated proce-
dure (e.g., stent implantation, thrombus visualized in culprit
vessel, dissection of culprit vessel), it was recommended that
subcutaneous injections of enoxaparin be restarted at least 2 h
after sheath removal and full hemostasis had been achieved;
the first injection was half of the fixed dose, and subsequent
injections every 12 h were at the full fixed dose.
If patients were referred for CABG, the study drug was to
be discontinued at least 12 h before the scheduled operation
and subsequent anticoagulation provided with unfractionated
heparin at the treating physician’s discretion.
Laboratory tests. At enrollment into the study, at hospital
discharge and at the final outpatient visit, measurement of
hemoglobin and a platelet count were obtained.
Before and after both the third and last weight-adjusted
doses of enoxaparin, blood specimens were obtained for
measurement of anti-Xa activity. Venous blood samples were
drawn by venipuncture before (trough) and 3 to 5 h after
(peak) the third weight-adjusted dose of enoxaparin and again
on the last day of weight-adjusted dosing. Blood samples were
collected in glass tubes (Becton Dickinson) containing 0.109
mol/liter sodium citrate and inhibitors of platelet activation as
an anticoagulant mixture (9:1 vol/vol) and were centrifuged at
3,000g for 15 min at 14°C. Plasma was frozen and stored at
280°C until analysis.
Plasma anti-Xa activity was determined by amidolytic assay
using the specific chromogenic substrate CBS 3139 and bovine
Factor Xa as reagents (Dioagnostica Stago) (16,17). The
enoxaparin standard calibrated against LMWH dose tier 1 was
used as a reference. The anti-Xa assay characteristics were as
follows: quantification limit 0.025 IU of anti-Xa/ml, linearity
over the 0.0- to 0.4-IU anti-Xa/ml calibration range, linear
response of serial dilution (0.4- to 10-IU anti-Xa/ml range),
Abbreviations and Acronyms
anti-IIa 5 anti-Factor IIa (thrombin)
anti-Xa 5 anti-Factor Xa
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
LMWH 5 low molecular weight heparin
NQMI 5 non–Q wave myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
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reproducibility within 4% to 12% and accuracy in the 96% to
110% range. All samples were analyzed in duplicate.
Concomitant medications. All patients received 325 mg of
aspirin at enrollment and 100 to 325 mg daily thereafter for the
duration of the study. Other antianginal therapy, including
beta-adrenergic blocking agents, nitrates and calcium channel
blocking agents, was administered at the discretion of the
treating physician.
Study end points. All study end points were reviewed and
classified by an Events Review Committee. The primary end
point, major hemorrhage occurring within 2 weeks of enroll-
ment, was defined as at least one of the following: 1) a clinically
overt hemorrhage resulting in a fall $3 gm/dl in hemoglobin;
or 2) a retroperitoneal, intracranial or intraocular hemorrhage.
Episodes of bleeding that were clinically overt but did not meet
these criteria were considered minor hemorrhages.
Efficacy end points were also ascertained at 2 weeks after
enrollment and included the following: 1) death (all-cause
mortality); 2) myocardial infarction not present at enrollment
was defined as elevation of creatine kinase, MB fraction, levels
above normal (twice normal after PTCA and five times normal
after CABG) or the development of new Q waves in two or
more contiguous leads (18); or 3) recurrent ischemia requiring
revascularization, defined as either rest pain followed by a
coronary revascularization procedure during the same hospital
period or rapid clinical deterioration (e.g., hypotension, car-
diac arrest, cardiogenic shock or persistent life-threatening
arrhythmia) necessitating emergency revascularization.
Statistical methods. Rates of major hemorrhage averaging
3.3% (95% confidence interval [CI] 0% to 6%) were found in
a review of the collective experience in 484 patients in trials
involving intravenous unfractionated heparin therapy for un-
stable angina/NQMI (7,19–21). A subset analysis in the TIMI
IIIB trial (18) revealed that hemorrhagic events occurred in
3.2% (95% CI 2.1% to 4.3%) of the 735 patients who received
heparin and placebo (invasive and conservative strategies
pooled). On the basis of the range of these data, an estimate of
the risk of major hemorrhage with unfractionated heparin in
previous clinical trials of ;4% was established. To obtain a
reliable estimate of the major hemorrhage rate, up to 500
patients were scheduled for enrollment into each dose tier to
ensure that at least 300 evaluable patients would be enrolled
(defined as receiving at least four consecutive weight-adjusted
doses of enoxaparin). An unacceptable rate of major hemor-
rhage for enoxaparin therapy was prospectively defined such
that the lower bound of its 90% CI was $4.0%. On the basis of
a minimal sample size of 300 patients for an evaluable cohort,
if at least 19 patients experienced a major hemorrhage (6.3%,
90% CI 4.0% to 8.7%) in a given dose tier, the anticipated rate
of major hemorrhage with unfractionated heparin would be
exceeded. Routine monitoring of the major hemorrhage rate
was performed by the Operations Committee during the
course of the trial. After 321 patients had been enrolled in dose
tier 1, 21 (6.5%) experienced a major hemorrhage, thus
exceeding the prespecified guidelines, and no further patients
were enrolled in that dose tier. The weight-adjusted dose was
reduced to 1.0 mg/kg every 12 h (dose tier 2), and a second
cohort of 309 patients was enrolled.
The data presented in this report compare the findings in
patients in dose tier 1 and dose tier 2. Because patients were
assigned to dose tiers sequentially rather than in a randomized
fashion, the proportion experiencing the primary end point in
the two dose tiers was compared by calculating the event rate
and its 95% CI. However, comparison of baseline characteris-
tics was performed using the chi-square test for categoric
variables and either two-tailed t tests or Wilcoxon rank sum
tests for continuous variables. Data for continuous variables
are presented as median (25th, 75th percentile). The cumula-
tive probability of developing the primary safety and primary
efficacy end points through 14 days was calculated by the
Kaplan-Meier method for both dose tiers; differences were
compared by the log-rank statistic. Differences associated with
a p value #0.05 were considered significant.
Results
Baseline characteristics. The characteristics of the patients
enrolled in the two dose tiers are shown in Table 1. No
significant differences were seen between the dose groups. The
majority of patients were white men with a previous history of
angina. The qualifying episode of ischemic discomfort oc-
curred a median of 12.6 h before enrollment in dose tier 1 and
21.1 h in dose tier 2. Approximately 80% of patients in both
groups had received aspirin in the week before enrollment.
Although 123 (38%) of patients in dose tier 1 and 163 (53%)
in dose tier 2 had received intravenous heparin during the
previous week, only 15 patients in dose tiers 1 (4.7%) and 2
(4.9%) had received it up to 1 h before enrollment into the
study.
Study drug treatment. The intravenous bolus dose of
30 mg of enoxaparin was received by 98% of patients in dose
tier 1 and 97% of patients in dose tier 2; 99% of patients
initiated dosing with the weight-adjusted regimen in both dose
tiers (Table 2). Weight-adjusted dosing was administered for a
median of 39 h in dose tier 1 and 27 h in dose tier 2. The trough
and peak anti-Xa activity levels were significantly higher in
dose tier 1 than dose tier 2 (Table 2). However, within both
dose tiers, the peak anti-Xa activity measured after the last
weight-adjusted dose was similar to that measured after the
third weight-adjusted dose.
Of the 321 patients in dose tier 1, 212 (66%) began
treatment with the fixed dose regimen, which was continued
for a median of 10 days. Similarly, of the 309 patients in the
second dose tier, 231 (75%) began treatment with the fixed
dose regimen, which was continued for a median of 11 days.
The total duration of treatment with study drug was nearly
2 weeks in both dose tiers (Table 2).
Compliance with study drug regimen. The duration of the
in-hospital phase was a median of 3 days in both dose tiers
(Table 3). Of the 321 patients in dose tier 1, 156 (49%)
discontinued dosing during the in-hospital phase. In 34 pa-
tients (11%), the study drug was stopped because of bleeding
1476 ANTMAN ET AL. JACC Vol. 29, No. 7
ENOXAPARIN IN UNSTABLE ANGINA June 1997:1474–82
as per the protocol and in 35 (11%) because of CABG. In 15
patients (5%) in dose tier 1, treatment was discontinued at the
patient’s request. Although a similar proportion of patients in
dose tier 2 had the study drug discontinued while in the
hospital for CABG (7%) or at their request (3%), a signifi-
cantly smaller proportion (6%) had treatment stopped because
of bleeding (p 5 0.03) than patients in dose tier 1.
The duration of the outpatient phase was a median of 10
days in both dose tiers (Table 3). The study drug was discon-
tinued in 27 (16%) and 32 (17%) patients during the outpa-
tient phase in dose tiers 1 and 2, respectively. However, ,5%
of patients requested discontinuation of treatment in both dose
tiers.
Safety analyses. Major hemorrhage occurred in 21 patients
(6.5%, 95% CI 4.2% to 10.0%) in dose tier 1 (Fig. 1). In 17
patients (5.3%), bleeding was at an instrumented site and
occurred a median of 34.8 h after a procedure. In 5 patients
(1.6%), bleeding occurred spontaneously (gastrointestinal [n 5
2], retroperitoneal [n 5 1], urinary tract [n 5 1], unidentified
[n 5 1]). One patient had both instrumented site and sponta-
neous bleeding. In 18 (86%) of 21 patients, the hemorrhage
occurred in the hospital, whereas in 3 it occurred within 4 days
of discharge.
Major hemorrhage occurred in six patients (1.9%, 95% CI
0.8% to 4.4%) in dose tier 2 (Fig. 1). In five patients (1.6%),
bleeding was at an instrumented site and occurred a median of
34.5 h after a procedure. In one patient (0.3%), a major
hemorrhage occurred spontaneously (skin). In four (67%) of
six patients, the hemorrhage occurred in the hospital, whereas
in two it occurred after discharge (within 24 h in one patient
and on day 10 in the other).
The cumulative probability of experiencing a major hemor-
rhage for patients undergoing a procedure and those not
undergoing a procedure is plotted in Figure 2. In both dose
tiers, the patients undergoing a procedure had a significantly
higher rate of major hemorrhage. The probability of a major
hemorrhage was significantly higher in dose tier 1 than dose
tier 2 patients undergoing a procedure (7.9% vs. 2.7%, p 5
0.011) but similar in the two dose tiers for those patients not
undergoing a procedure (1.5% vs. 0%, p 5 NS).
Several consistent observations across both tiers were made
in the patients experiencing a major hemorrhage (Table 4).
They tended to be older, lighter in weight and were more likely
to have received intravenous nitrates, unfractionated heparin
(for catheterization procedures) and other antiplatelet agents
in addition to aspirin. In addition, the peak anti-Xa levels
tended to be higher in patients experiencing a major hemor-
rhage than those not experiencing a major hemorrhage. The
peak anti-Xa levels during the study were highest in dose tier
1 patients who experienced a major hemorrhage (Table 4).
Thrombocytopenia (platelet count ,100,000/mm3) oc-
curred in two patients (0.7%) in dose tier 2 but in no patients
in dose tier 1.
Efficacy analyses. As shown in Table 5, the incidence,
through 14 days, of the sum of death, nonfatal (re)infarction or
recurrent ischemia requiring revascularization was similar in
the two dose tiers. No significant differences were observed in
the distribution of the elements of the composite efficacy end
point. Of the 18 patients (5.6%) in dose tier 1 experiencing at
least one of the components of the efficacy end point by day 14
after enrollment, the event occurred before discharge in 15 and
Table 1. Baseline Characteristics
Dose Tier 1
(n 5 321)
Dose Tier 2
(n 5 309)
Weight-adjusted dose (mg/kg
every 12 h)
1.25 1.0
Age (yr) 63.0 (53.0, 71.0) 64.0 (56.0, 71.0)
Gender
Male 206 (64) 193 (63)
Female 115 (36) 116 (38)
Weight (kg)
Race 84.0 (73.0, 95.0) 81.0 (70.0, 94.0)
White 257 (80) 255 (83)
Nonwhite 64 (20) 54 (17)
Diabetes 89 (28) 114 (37)*
Current smoker 93 (29) 70 (23)
Hypertension 188 (59) 187 (61)
Previous cardiac history
Angina 228 (71) 217 (70)
CCSC
III 45 (21) 26 (13)
IV 58 (27) 65 (32)
Previous angiogram with
stenosis $50%
173 (55) 175 (58)
PTCA 104 (33) 90 (29)
CABG 76 (24) 82 (27)
MI 118 (37) 124 (41)
Medications in previous wk
Aspirin 258 (80) 254 (82)
IV nitrates 78 (24) 82 (27)
Beta-blocker 151 (47) 153 (50)
Calcium blocker 135 (42) 134 (43)
IV heparin 123 (38) 163 (53)*
Characteristics of presenting
illness
Time since chest pain (h) 12.6 (6.0, 26.8) 21.1 (8.3, 53.2)*
Duration of qualifying pain
episode (min)
60 (20.0, 150.0) 45 (15.0, 170.0)
No. of episodes $5 min in
previous 24 h
1.0 (1.0, 2.0) 1.0 (0, 2.0)
Pattern of pain
Rest 200 (62) 187 (61)
Crescendo 70 (22) 61 (20)
New onset 51 (16) 60 (19)
ECG changes
ST segment depression 53 (17) 37 (12)
ST segment elevation 20 (6) 30 (10)
T wave inversion 82 (26) 73 (24)
LBBB 11 (3) 10 (3)
None 191 (60) 197 (64)
*p , 0.05. Data presented are number (%) of patients or median (25th, 75th
percentile), unless otherwise indicated. CABG 5 coronary artery bypass graft
surgery; CCSC 5 Canadian Cardiovascular Society classification; ECG 5
electrocardiographic; IV 5 intravenous; LBBB 5 left bundle branch block;
MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary
angioplasty.
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between 2 and 5 days of discharge in 3 patients. Similarly, of
the 16 patients (5.2%) in dose tier 2 with efficacy end points,
the event occurred before hospital discharge in 13 and between
1 and 6 days after discharge in 3 patients. The cumulative
probability of experiencing an efficacy end point event in the
two dose tiers is plotted in Figure 3. A similar temporal pattern
was observed with the majority of events occurring within the
first 8 days of enrollment.
Discussion
Encouraging results have been reported (22,23) in pilot
trials of treatment of patients with unstable angina using doses
of LMWHs that yield anti-Xa activity levels needed for pro-
phylaxis against deep vein thrombosis. Recent clinical trials
(24,25) of dalteparin and nadroparin in unstable angina with
doses higher than those used for prevention of venous disor-
ders have shown these agents to be superior to aspirin alone
for preventing the composite end point of death or nonfatal
Figure 1. Incidence of major hemorrhage through day 14. The rate of
major hemorrhage was 6.5% in dose tier 1 and 1.9% in dose tier 2. In
both dose tiers, the majority of episodes of major bleeding occurred at
instrumented sites (solid portions of bars). Open portions of bars 5
spontaneous bleeding; error bars 5 95% confidence interval for the
major hemorrhage rates. Pts 5 patients; Q 5 every.
Table 2. Study Drug Treatment
Dose Tier 1
(n 5 321)
Dose Tier 2
(n 5 309)
WA dosing
IV bolus (30 mg) administered 316 (98) 301 (97)
WA dose every 12 h (mg/kg) 1.25 1.0
WA dose started 320 (99) 308 (99)
Duration of WA doses (h) 39 (26, 61) 27 (12, 46)*
Total no. of WA doses 4.0 (3.0, 6,0) 3.0 (2.0, 5.0)*
Anti-Xa activity (IU/ml)
3rd WA dose
Trough 0.6 (0.3, 1.0) [n 5 216] 0.5 (0.3, 0.7) [n 5 164]†
Peak 1.5 (1.2, 1.7) [n 5 227] 1.0 (0.9, 1.2) [n 5 163]†
Last WA dose
Trough 0.8 (0.4, 1.0) [n 5 115] 0.6 (0.4, 0.9) [n 5 45]†
Peak 1.6 (1.1, 1.8) [n 5 103] 1.1 (1.0, 1.2) [n 5 46]†
Fixed dose treatment
Dose (mg SC every 12 h)
,65 kg 40 40
$65 kg 60 60
Fixed dose started 212 (66) 231 (75)
Duration of fixed dose Rx (days) 10.0 (7.0, 12.0) 11.0 (6.0, 12.0)
Total duration of treatment (days) 12.0 (3.0, 13.0) 13.0 (3.0, 14.0)
*p , 0.05, †p , 0.01 versus Dose Tier 1. Data presented are number (%) of patients or median (25th, 75th
percentile), unless otherwise indicated. Anti-Xa 5 anti-Factor Xa; Rx 5 treatment; SC 5 subcutaneously; WA 5 weight
adjusted.
Table 3. Compliance With Study Drug Treatment
Dose Tier 1
(n 5 321)
Dose Tier 2
(n 5 309)
In-hospital phase
Duration of treatment (days) 3.0 (2.0, 4.0) 3.0 (1.0, 4.0)
Study drug discontinued 156 (49) 123 (40)
Reasons for discontinuation
,50% stenosis on angiogram 37 (11) 27 (9)
Physician preference 16 (5) 20 (7)
Patient preference 15 (5) 9 (3)
CABG 35 (11) 23 (7)
Hemorrhage 34 (11) 18 (6)*
Adverse event 7 (2) 9 (3)
Other 12 (4) 16 (5)
Outpatient phase n 5 166 n 5 186
Duration of treatment (days) 10.0 (8.0, 12.0) 10.0 (9.0, 12.0)
Study drug discontinued 27 (16) 32 (17)
Reasons for discontinuation
Physician preference 2 (2) 5 (3)
Patient preference 6 (4) 10 (5)
Death 1 (1) 0 (0)
Hemorrhage 0 (0) 0 (0)
Adverse event 3 (2) 0 (0)
Other 14 (8) 12 (7)
*p 5 0.03 versus Dose Tier 1. Data presented are number (%) of patients or
median (25th, 75th percentile). CABG 5 coronary artery bypass graft surgery.
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ischemia/infarction without an increase in the rate of major
hemorrhage compared with that expected with unfractionated
heparin. However, at the initial dose of dalteparin used in the
Fragmin During Instability in Coronary Artery Disease
(FRISC) study (25) (150 IU/kg every 12 h), a 6% incidence of
major bleeding was observed that was decreased to 0.8% when
Figure 2. Cumulative probability of experiencing a ma-
jor hemorrhage through 14 days. The probability, calcu-
lated by the Kaplan-Meier method, of developing a
major hemorrhage is shown for patients enrolled in dose
tier 1 (dashed lines) and dose tier 2 (solid lines). For
both dose tiers, patients were further stratified by
whether catheterization was performed. In those pa-
tients undergoing catheterization, the abscissa repre-
sents the number of days from the first invasive proce-
dure, whereas in those not undergoing catheterization, it
represents the number of days since enrollment in the
trial. The risk of developing a major hemorrhage was
significantly higher in patients in dose tier 1 undergoing
a procedure (7.9%) than those in dose tier 2 undergoing
a procedure (2.7%, p , 0.01 by log-rank test). The risk
of major hemorrhage was lower in patients not under-
going a procedure and was similar in the two dose tiers
(p 5 NS).
Table 4. Characteristics of Patients With Major Hemorrhage
Dose Tier 1
(WA dose 1.25 mg/kg every 12 h)
Dose Tier 2
(WA dose 1.0 mg/kg every 12 h)
Major Hemorrhage
(n 5 21)
No Major Hemorrhage
(n 5 299)
Major Hemorrhage
(n 5 6)
No Major Hemorrhage
(n 5 303)
Age (yr) 70.0 (62.0, 70.0)* 63.0 (53.0, 71.0) 65.5 (64.0, 71.0) 64.0 (56.0, 71.0)
Gender
Male 12 (57) 194 (65) 3 (50) 190 (63)
Female 9 (43) 106 (35) 3 (50) 113 (37)
Weight (kg) 77.0 (67.0, 91.0) 84.0 (73.0, 95.0) 71.0 (68.7, 73.0) 81.0 (70.0, 94.0)
Creatinine (mg/dl) 1.1 (0.9, 1.4) 1.0 (0.8, 1.1) 1.3 (0.9, 1.6) 1.0 (0.8, 1.1)
Anti-Xa (IU/liter)
3rd WA dose
Trough 0.5 (0.3, 1.0)
[n 5 14]
0.6 (0.3, 1.0)
[n 5 202]
0.7 and 1.0
[n 5 2]
0.5 (0.3, 0.7)
[n 5 162]
Peak 1.8 (1.6, 2.1)
[n 5 14]†
1.4 (1.2, 1.7)
[n 5 213]
1.2 and 1.9
[n 5 2]
1.0 (0.9, 1.2)
[n 5 161]
Last WA dose
Trough 0.6 (0.3, 0.8)
[n 5 7]
0.8 (0.4, 1.0)
[n 5 106]
0.3 and 1.5
[n 5 2]
0.6 (0.3, 0.9)
[n 5 43]
Peak 2.0 (1.3, 2.3)
[n 5 4]
1.6 (1.1, 1.8)
[n 5 99]
1.0 and 1.8
[n 5 2]
1.1 (0.9, 1.1)
[n 5 44]
Concomitant medications
During initial 48 h
Aspirin 21 (100) 281 (94) 6 (100) 285 (94)
IV nitrates 9 (43) 108 (36) 3 (50) 87 (29)
IV heparin 8 (38) 34 (11) 3 (50) 47 (16)
Other antiplatelet 3 (14) 26 (9) 1 (17) 28 (9)
.48 h to hospital discharge
Aspirin 19 (91) 252 (84) 5 (83) 217 (72)
IV nitrates 7 (33) 49 (16) 3 (50) 30 (10)
IV heparin‡ 9 (43) 68 (23) 0 (0) 34 (11)
Other antiplatelet 4 (19) 40 (13) 2 (33) 26 (9)
At hospital discharge
Aspirin 17 (81) 240 (80) 6 (100) 269 (89)
Other antiplatelet 3 (14) 29 (10) 2 (33) 32 (11)
*p , 0.05, †p , 0.01, major hemorrhage versus no major hemorrhage in Dose Tier 1. ‡Administered in support of diagnostic catheterization or interventional
procedures, or both. Data presented are number (%) of patients or median (25th, 75th percentile). Abbreviations as in Tables 1 and. 2.
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the dose was reduced (120 IU/kg every 12 h), underscoring the
need to perform dose-ranging trials as new antithrombotic
regimens are investigated for unstable angina/NQMI.
The findings of the TIMI-11A trial indicate that treatment
with enoxaparin during the hospital phase using a weight-
adjusted regimen of 1.25 mg every 12 h is associated with a rate
of major hemorrhage (6.5%) higher than that seen in trials
with unfractionated heparin (4%) (7,18–21). The rate of
bleeding in dose tier 1 was greatest in patients undergoing a
procedure (7.9%) and markedly exceeded the rates observed
in dose tier 1 patients not undergoing a procedure as well as
the subsets of dose tier 2 patients who did and did not undergo
a procedure (Fig. 2).
Anti-Xa activity. The antithrombotic activity of enoxaparin
appears to be due to a combination of inhibition of thrombin
generation (anti-Xa activity), inhibition of thrombin activity
(anti-IIa activity), inhibition of platelet aggregation and release
of tissue factor pathway inhibitor (8,11,26). No single measure-
ment of hematologic function has emerged as the best indica-
tor of the level of antithrombotic activity of enoxaparin.
However, the most frequently measured variable is anti-Xa
activity, which has been proposed as an important metric of the
biologic activity of LMWHs in general.
Although in vitro measurements of the anti-Xa/anti-IIa
activity ratio for enoxaparin are in the 3:1 range, the kinetics of
clearance of these two activities are different in vivo, producing
in vivo anti-Xa/anti-IIa ratios that change over time after
subcutaneous injections. Because the clearance of anti-IIa
activity of enoxaparin is .2.5 times as fast as that of anti-Xa
activity, in vivo anti-Xa/anti-IIa activity ratios of 12:1 may be
achieved several hours after injection of a dose (27).
The attainment of higher peak anti-Xa activity levels in
dose tier 1 than in dose tier 2 is consistent with the previously
described (15) dose-dependent increase in anti-Xa activity with
enoxaparin. On the basis of clearance rates of anti-Xa and
anti-IIa activity, it is likely that for a greater proportion of time
after a weight-adjusted dose of enoxaparin, patients in dose
tier 1 might have not only had higher levels of anti-Xa activity
than patients in dose tier 2, but also experienced longer periods
of relatively greater inhibition of thrombin generation than
inhibition of thrombin activity. This would be expected to be
less well tolerated in patients with a recent violation of vascular
integrity where thrombin generation is needed to maintain the
integrity of a hemostatic plug. The observations in Figure 2 are
consistent with this hypothesis because the higher rate of major
hemorrhage in dose tier 1 was observed predominantly in
patients undergoing instrumentation.
As shown in Tables 2 and 4, peak anti-Xa activity levels
after the last weight-adjusted dose were similar to those
measured after the third weight-adjusted dose. This suggests
that there is no accumulation of anti-Xa activity with multiple
injections and that a weight-adjusted dose of 1.0 mg/kg every
12 h is unlikely to yield anti-Xa levels in the range where the
risk of major hemorrhage is increased, even in patients under-
going catheterization procedures (Fig. 2). Further measures
that are likely to minimize the risk of instrumented site
bleeding include 1) meticulous attention to the interval be-
tween doses (e.g., at least 12 h) to avoid “stacking” of
additional anti-Xa activity on top of that from the previous
injection, and 2) allowing at least 7 to 8 h to elapse before
pulling vascular access sheaths to avoid removal when anti-Xa
activity is maximal after a dose (e.g., 3.5 to 5 h).
The pilot experience in the TIMI 11A trial with respect to
clinical outcome through 14 days suggests that the lower risk of
major hemorrhage with a weight-adjusted dose of 1.0 mg/kg
every 12 h was not achieved at the expense of efficacy. The data
presented in Table 5 reveal a similar rate of the composite
primary efficacy end point in the two dose tiers. The temporal
pattern of development of clinical events with both dose
regimens of enoxaparin showed the greatest incidence of
events over the first 8 days followed by a slower rate of
development of events through day 14 (Fig. 3). There was no
abrupt increase in events after hospital discharge (at a median
of 3 days from enrollment). Thus, there was no rebound in
events in association with a reduction in the level of antithrom-
botic therapy from the weight-adjusted in-hospital regimen to
the fixed-dose outpatient regimen of enoxaparin. Follow-up
Figure 3. Cumulative probability of experiencing primary efficacy end
point. Time to development of either death, recurrent myocardial
infarction or recurrent ischemia requiring revascularization is plotted
(Kaplan-Meier method) for patients in dose tier 1 (dashed line) and
dose tier 2 (solid line). The rate of development of events was highest
during the first 8 days. There was no abrupt increase in the rate of
events after the transition from the inpatient to outpatient phase of
treatment (at a median of 3.0 days) or after discontinuation of the
outpatient phase of treatment (at a median of an additional 10 days).
See text for further discussion.
Table 5. Clinical Outcome Through 14 Days*
Dose Tier 1
(n 5 321)
Dose Tier 2
(n 5 309)
Death 7 (2.2) 2 (0.6)
MI 7 (2.2) 9 (2.9)
Recurrent ischemia requiring
revascularization
4 (1.2) 5 (1.6)
Any of above 18 (5.6) 16 (5.2)
*p 5 NS for all comparisons. Data presented are number (%) of patients.
MI 5 myocardial infarction.
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data to date also fail to reveal any rebound increase in events
after discontinuation of the outpatient enoxaparin regimen at
day 14 (Fig. 3). These observations compare favorably with
reports (28,29) of a rebound in the rate of clinical events after
discontinuation of infusions of unfractionated heparin for
unstable angina.
Clinical implications. Enoxaparin is an attractive thera-
peutic agent for the treatment of unstable angina. The high
anti-Xa/anti-IIa activity ratio offers the potential advantage
over unfractionated heparin of greater inhibition of the coag-
ulation cascade at a more proximal step, leading to a combined
reduction in thrombin generation and thrombin activity. The
high bioavailability with subcutaneous administration and pro-
longed duration of action of enoxaparin make the simple
regimen of twice-daily injections for both inpatients and out-
patients a viable possibility. The results of the TIMI-11A trial
have defined a weight-adjusted acute phase regimen of
1.0 mg/kg every 12 h as a well tolerated dose and also indicate
a high rate of patient compliance with the home treatment
phase. A Phase III trial in patients with unstable angina, the
TIMI 11B trial, is now underway to examine the relative
benefits of a strategy of uninterrupted subcutaneous enoxapa-
rin during both the acute and chronic phases of treatment
versus the current practice of administering intravenous un-
fractionated heparin only during the acute phase.
Appendix
Participating Investigators and Clinical Centers for
the TIMI 11A Trial
Study Chairman’s Office: Brigham and Women’s Hospital, Harvard Medical
School, Boston, Massachusetts. Study Chairman: Eugene Braunwald, MD; Prin-
cipal Investigator: Elliott M. Antman, MD; Project Director: Carolyn H. McCabe,
BS; Project Manager: Susan J. Marble, RN, MS; Co-Investigator: Christopher P.
Cannon, MD.
Sponsor: Rhoˆne-Poulenc Rorer, Collegeville, Pennsylvania. Senior Associate
Director, Cardiovascular Diseases: Jerome Premmereur, MD; Project Director:
Mark Todd.
Data Coordinating Center: Corning Besselaar, Inc., Princeton, New Jersey.
Project Director: Larry Meinert, MD, MPH; Coordinator: Iris Houlihan; Biosta-
tistician: Toyoko Oguri, MS; Data Management: Juan Torres; Programmer:
Lawrence Rausch.
Events Review Committee: Michael Gibson, MD; Elliott M. Antman, MD,
Christopher P. Cannon, MD.
Anti-Xa Core Laboratory: Croix de Berney, France: Francoise Collignon,
PhD.
Steering Committee: The members of the Steering Committee include
members of the Study Chairman’s Office and the Principal Investigators from the
TIMI 11A Clinical Centers.
*Clinical Centers. Washington County Medical Center, Hagerstown, Maryland:
Gary Papuchis, MD, Sharon Etter. Munroe Regional Medical Center, Ocala,
Florida: Robert Feldman, MD, Brandi Merchant. Jewish Hospital, Saint Louis,
Missouri: Patricia Cole, MD, Lynn Coulter. Baptist Medical Center/Alabama,
Montgomery, Alabama: Paul Moore, MD, Mark Platt, Ernest Parker. Sarasota
Memorial Hospital, Sarasota, Florida: Martin Frey, MD, Torey Browning. Uni-
versity of Alabama, Birmingham, Alabama: William Rogers, MD, Terri Morgan.
University of Minnesota Hospitals and Clinics, Minneapolis, Minnesota: David
Laxson, MD, Cheryl Iacarella, Betsy Christenson. Baystate Medical Center,
Springfield, Massachusetts: Marc Schweiger, MD, Barbara Burkott, Deborah
Warwick. Brookdale Hospital Medical Center, Brooklyn, New York: Hal Chadow,
MD, Maureen Matheson. Hennepin County Medical Center, Minneapolis, Minne-
sota: Timothy Henry, MD, Charlene Bosjolie, Lorri Knox. St. Luke’s/Roosevelt
Hospital Center, New York, New York: Judith S. Hochman, MD, Robert Leber,
MD, Angela Palozzi, MD, Mary McAnulty, Deborah Tormey. Nassau County
Medical Center, East Meadow, New York: Israel Freeman, MD, Laura Teplitz,
Margaret Alex. St. Paul’s Hospital, Vancouver, British Columbia, Canada: Chris-
topher Thompson, MD, Charlene Hooper, Brenda Mercier. University of Texas/
Medical Branch at Galveston, Galveston, Texas: David Cutler, MD, Dana Sprott.
Alta Bates Medical Center, Berkeley, California: Robert Greene, MD, Eileen
Healy, Vickie Perry. University of Massachusetts Medical Center, Worcester,
Massachusetts: Richard C. Becker, MD, Steven Ball. Brigham and Women’s
Hospital, Boston, Massachusetts: James M. Kirshenbaum, MD, Jill Jarvis. Central
Suffolk Hospital, Riverhead, New York: Thomas Falco, MD, Kate Rush, Cindy
Zaleski. Emerson Hospital, Concord, Massachusetts: Steven Herson, MD, Gail
Carey. Hartford Hospital, Hartford, Connecticut: Raymond McKay, MD, Jill
Cloutier. Henry Ford Hospital, Detroit, Michigan: Steven Borzak, MD, A.
Christian Held, MD, Stephen T. Smith, MD, Lori Douthat. Hospital of the Good
Samaritan, Los Angeles, California: Thomas Shook, MD, Lucille Junio. Hunter-
don Medical Center, Flemington, New Jersey: Austin Kutscher, Jr., MD, Janet
McMahon. Michigan Heart and Vascular Institute, Ypsilanti, Michigan: James
Bengtson, MD, MPH, Mary Adolphson. SUNY/Downstate University Hospital,
Brooklyn, New York: Tak Kwan, MD, Rosa Julien. Vancouver Hospital and Health
Sciences Center, Vancouver, British Columbia, Canada: Anthony Fung, MD,
Christopher Buller, MD, Cheryl Davies; Catherina van Beek. Cedars-Sinai
Medical Center, Los Angeles, California: Prediman Shah, MD, Mitchell Gheo-
rghiu, MD. Community Hospital of Tallahassee, Tallahassee, Florida: Patrick
Bianchi, MD, Kim Sanders. LDS Hospital, Salt Lake City, Utah: Jeffrey Ander-
son, MD, Ann Allen. Ohio State University Medical Center, Columbus, Ohio:
Raymond Magorien, MD, Laurie McCloud, AnnMarie Thomas. West Roxbury
Veterans Affairs Medical Center, West Roxbury, Massachusetts: C. Michael Gibson,
MD, Diane Lapsley. Atlanta Veterans Affairs Medical Center, Decatur, Georgia:
Jeffrey Marshall, MD, Alberta Lane. Loyola University Medical Center, Maywood,
Illinois: Eric Grassman, MD, Ellen Galbraith. Miami Veterans Affairs Medical
Center, Miami, Florida: Simon Chakko, MD, Donald Koggan, MD. Presbyterian
Hospital of Dallas, Dallas, Texas: Darryl Kawalsky, MD, Malou Arnold. St.
Vincent’s Hospital, Worcester, Massachusetts: Richard Bishop, MD, Tammy
Brunelle, Patricia Arsenault. University of Texas/Hermann Hospital, Houston,
Texas: H. Vernon Anderson, MD, Lynette Weigelt, Julie Manning. Winthrop
University Hospital, Mineola, New York: Richard Steingart, MD, Suzanne
Bilodeau, Mary Ellen Coglianese. Doctor’s Hospital of Sarasota, Sarasota,
Florida: Martin Frey, MD, Torey Browning. Mary Rutan Hospital, Bellafontaine,
Ohio: Evan W. Dixon, MD, Ronda Neal. Montefiore Medical Center, Bronx, New
York: Hiltrud Mueller, MD, Joseph Cosico, Linda Kunkel. St. John’s Queens
Hospital, Elmhurst, New York: Gregory Macina, MD, Marie Kikel, Marya Pier.
Sturdy Memorial Hospital, Attleboro, Massachusetts: Charles Peter Rogers, MD,
Susan Dolan, Suzanne Nordstrom. Scripps Clinic and Research Foundation, La
Jolla, California: Paul Tierstein, MD, Glenda Haas. West Los Angeles Veterans
Affairs Medical Center, Los Angeles, California: Malcolm Bersohn, MD, Carole
Silbar.
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